TY - JOUR
T1 - Drug approval highlights for 2003
AU - Laustsen, Gary
AU - Wimett, Lynn
PY - 2004/2
Y1 - 2004/2
N2 - In the past 12 months, the FDA has approved important new pharmaceutical drugs and devices of particular interest to primary health care providers. The drugs include: Oxytrol (for urinary incontinence), Valtrex (for reducing the risk of heterosexual transmission of genital herpes), Femring (for vaginal delivery of hormone therapy), Uroxatral (for benign prostatic hypertrophy), Levitra (for erectile dysfunction), Flumist (for preventing influenza), Xolair (for asthma), Raptiva (for psoriasis), Cubicin (for skin infections), Crestor (for hypercholesterolemia), and Coreg (for severe heart failure).
AB - In the past 12 months, the FDA has approved important new pharmaceutical drugs and devices of particular interest to primary health care providers. The drugs include: Oxytrol (for urinary incontinence), Valtrex (for reducing the risk of heterosexual transmission of genital herpes), Femring (for vaginal delivery of hormone therapy), Uroxatral (for benign prostatic hypertrophy), Levitra (for erectile dysfunction), Flumist (for preventing influenza), Xolair (for asthma), Raptiva (for psoriasis), Cubicin (for skin infections), Crestor (for hypercholesterolemia), and Coreg (for severe heart failure).
UR - http://www.scopus.com/inward/record.url?scp=2342435060&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=2342435060&partnerID=8YFLogxK
U2 - 10.1097/00006205-200402000-00002
DO - 10.1097/00006205-200402000-00002
M3 - Article
C2 - 14872168
AN - SCOPUS:2342435060
SN - 0361-1817
VL - 29
SP - 8
EP - 21
JO - Nurse Practitioner
JF - Nurse Practitioner
IS - 2
ER -